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Abstract A tissue inhibitor of metalloproteinases-2 (TIMP-2)-
independent mechanism for generating the ¢rst activational
cleavage of pro-matrix metalloproteinase-2 (MMP-2) was iden-
ti¢ed in membrane type-1 MMP (MT1-MMP)-transfected
MCF-7 cells and con¢rmed in TIMP-2-de¢cient ¢broblasts.
In contrast, the second MMP-2-activational step was found to
be TIMP-2 dependent in both systems. MMP-2 hemopexin
C-terminal domain was found to be critical for the ¢rst step
processing, con¢rming a need for membrane tethering. We pro-
pose that the intermediate species of MMP-2 forms the well-
established trimolecular complex (MT1-MMP/TIMP-2/MMP-
2) for further TIMP-2-dependent autocatalytic cleavage to the
fully active species. This alternate mechanism may supplement
the traditional TIMP-2-mediated ¢rst step mechanism.
) 2003 Published by Elsevier B.V. on behalf of the Federation
of European Biochemical Societies.
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1. Introduction
Matrix metalloproteinases (MMPs) are a family of structur-
ally related proteolytic enzymes, which collectively degrade all
components of the extracellular matrix (ECM), as well as a
growing number of speci¢c cell modulators such as growth
factors, cell adhesion molecules, receptors, and other protein-
ases [1,2]. All MMPs possess a signal peptide, a propeptide,
an N-terminal catalytic domain, and most also possess a he-
mopexin C-terminal domain (HXCD) [2,3]. There are six
membrane-type MMPs (MT-MMPs), four of which possess
a putative transmembrane domain and a short cytoplasmic
tail at their C-terminal region. The transmembrane domain
in MT1-, MT2-, MT3-, and MT5-MMP anchors the enzyme
to the cytoplasmic membrane, localizing proteolytic activity to
the cell surface. An important role of several of the MT-
MMPs is the cell-localized activation of pro-MMP-2. The
activity of MMPs is also regulated by a family of four inhib-
itors known as the tissue inhibitors of metalloproteinases
(TIMPs) [4].
In the current model for MT1-MMP-mediated pro-MMP-2
activation (Fig. 4), active MT1-MMP anchored on the cell
surface acts as a receptor for TIMP-2, the TIMP-2 molecule
binding through its N-terminal domain to the active site of
MT1-MMP. This binary complex acts as a receptor for pro-
MMP-2, the TIMP-2 C-terminal domain binding to the
HXCD of pro-MMP-2. A free MT1-MMP molecule in close
proximity then cleaves the pro-MMP-2 propeptide at the
Asn37^Leu38 bond, generating an intermediate species [5^8].
Further autocatalytic proteolysis generates the fully active en-
zyme [5,9,10]. Optimum TIMP-2 levels are required for e⁄-
cient pro-MMP-2 activation [6^8]. MT1-MMP dimerization
via MT1-MMP’s HXCD or cytoplasmic tail is also essential
for pro-MMP-2 activation [11^13]. We provide data of a sup-
plementary, TIMP-2-independent ¢rst step mechanism, and
for the ¢rst time focus on the role of TIMP-2 in the second
activational step.
2. Materials and methods
2.1. Recombinant proteins and reagents
Recombinant TIMP-2 was kindly provided by Dr. Chris Overall
(UBC, Vancouver, BC, Canada). Recombinant full-length pro-
MMP-2 expressed in a vaccinia virus system (rMMP-2) was a kind
gift from Dr. Rafael Fridman (Wayne State University, Detroit, MI,
USA) [14]. Recombinant ala+TIMP-2 was kindly provided by Dr.
William Stetler-Stevenson (NCI, NIH, Bethesda, MD, USA) [15].
Recombinant TIMP-1 and GM6001 were purchased from Chemicon
(Boronia, Australia). Concanavalin A (Con A), 4-aminophenylmercu-
ric acetate and phorbol 12-myristate 13-acetate (PMA) were pur-
chased from Sigma-Aldrich (Castle Hill, Australia).
MMP-2 and MMP-2 vHXCD were obtained from conditioned me-
dia of MCF-7 cells stably transfected with expression vectors (pCHC6
[16]) encoding full-length MMP-2 or MMP-2 from which the HXCD
(residues 469^631) was deleted.
2.2. Cell culture
ML20-MT1 cells [17] were generated by stably transfecting MT1-
MMP cDNA under the control of the CMV promoter (pCNCMT1-
MMP) into an MCF-7 clone previously transfected with L-galactosi-
dase (ML20) [16]. ML20-MT1 cells were maintained in Dulbecco’s
Modi¢ed Eagle’s medium (DMEM; Life Technologies, New Zealand)
supplemented with 10% fetal bovine serum (FBS; JRH Biosciences,
Lenexa, KS, USA).
TIMP-2þ=þ and TIMP-2vEx2;3=vEx2;3 (lacking exons 2 and 3 of the
TIMP-2 gene) primary mouse ¢broblasts [18] were generously pro-
vided by Dr. John Caterina (NIDCR Matrix Metalloproteinase
Unit NIH, Bethesda, MD, USA). Ras/myc transformed TIMP-23=3
mouse ¢broblasts lacking the entire TIMP-2 gene [19] were kindly
0014-5793 / 03 / $22.00 N 2003 Published by Elsevier B.V. on behalf of the Federation of European Biochemical Societies.
doi:10.1016/S0014-5793(03)01094-9
*Corresponding author. Fax: (61)-3-9288 2605.
E-mail address: rik@medstv.unimelb.edu.au (E.W. Thompson).
1 Present address: Department of Biochemistry and Molecular
Biology, University of British Columbia, J.B. Macdonald Building,
2199 Wesbrook Mall, Vancouver, BC, Canada V6T 1Z3.
Abbreviations: Con A, concanavalin A; ECM, extracellular matrix;
HXCD, hemopexin C-terminal domain; MMP, matrix metallopro-
teinase; MT-MMP, membrane-type matrix metalloproteinase; SFM,
serum-free media; TIMP, tissue inhibitor of metalloproteinases
FEBS 27729 9-10-03
FEBS 27729 FEBS Letters 553 (2003) 457^463
provided by Dr. Paul Soloway (Roswell Park Cancer Institute, Buf-
falo, NY, USA). Fibroblasts were maintained in DMEM supple-
mented with 10% FBS and penicillin/streptomycin.
2.3. Gelatin zymography
Zymography was performed using a 10% polyacrylamide resolving
gel co-polymerized with 1 mg/ml gelatin (BDH Laboratory Supplies,
Poole, UK) in the large gel format (15 cmU12 cm) as previously
described [20].
2.4. Western analysis
For MMP-2 Western analysis, MMP-2 from the conditioned media
of ML20-MT1 cells was concentrated using gelatin^agarose beads
(Sigma-Aldrich) overnight at 4‡C. The beads were then washed and
eluted with 4U sodium dodecyl sulfate sample bu¡er. All samples (for
MMP-2 or TIMP-2 Western analysis) were prepared with 100 mM
dithiothreitol as reducing agent and separated using a 10% polyacryl-
amide resolving gel. After electrophoresis, proteins were transferred to
a polyvinylidene £uoride membrane for 2 h at 100 V. Membranes
were then blocked in 5% (w/v) skim milk in Tris-bu¡ered saline
(TBS) containing 0.1% (v/v) Tween 20 (TBS^Tween 20) overnight.
Membranes were probed either with a mouse anti-human TIMP-2
antibody (clone #67-4H11, Chemicon) or a rabbit anti-human poly-
clonal MMP-2 antibody (PAB 753) (kindly provided by Dr. Jack
Windsor, University of Alabama at Birmingham) for 1 h then washed
in TBS^Tween 20. Membranes were then probed with a horseradish
peroxidase-conjugated goat anti-mouse (Pierce, Darra, Australia) sec-
ondary antibody (for TIMP-2) or a goat anti-rabbit (Pierce) second-
ary antibody (for MMP-2) for 1 h, then washed in TBS^Tween 20.
Detection was performed using the SuperSignal West Pico Chemilu-
minescent Substrate system (Pierce).
3. Results
3.1. TIMP-2 potentiation of the second step of pro-MMP-2
activation in ML20-MT1 cells
ML20-MT1 cells do not produce MMP-2, therefore exoge-
nous recombinant pro-MMP-2 was added to these cultures.
TIMP-2 production by these cells was low and only detectable
by Western blot after concentration of the conditioned me-
dium (approximately 200 ng/ml TIMP-2 produced by 1U104
cells in 100 Wl for 24 h as determined by Western analysis
using a standard curve of known TIMP-2 concentration,
data not shown). Transfection of MT1-MMP caused weak
pro-MMP-2 activation generating both intermediate and fully
active species, and this was greatly increased in response to
Con A (Fig. 1a). Addition of recombinant TIMP-2 preferen-
tially increased the second step of pro-MMP-2 activation at
the lower concentrations, although a slight increase in the ¢rst
step product was also seen (Fig. 1a). In order to con¢rm the
results obtained by zymography in Fig. 1a, we also analyzed
some of these samples by Western analysis for MMP-2. Fig.
1b demonstrates that similar results were obtained either by
zymography or Western analysis for MMP-2 with a biphasic
response to TIMP-2. Because zymography is more sensitive
than Western analysis, MMP-2 from the conditioned media
was concentrated using gelatin^agarose beads for Western
analysis. The levels of the intermediate form of MMP-2
were too low to detect by Western analysis using the ML20-
MT1 cells. The relative levels of pro- and active MMP-2 ob-
served by Western blot were determined by scanning densi-
tometry and plotted as a percentage of the fully active en-
zyme.
In order to verify that TIMP-2 was indeed preferentially
a¡ecting the second step, and not simply increasing the ¢rst
step thereby generating more intermediate product that would
be rapidly processed to the fully active species, we added ex-
cess TIMP-1 to selectively block the second step. We used
concentrations of TIMP-1 that have been shown previously
not to block MT-MMPs, as TIMP-1 is a very poor inhibitor
of MT1-MMP [21^23]. TIMP-2 alone selectively increased the
second step, with only a minor accumulation of the intermedi-
ate form observed with co-addition of TIMP-1 (Fig. 1c), con-
¢rming that the e¡ects seen in the second step are not due to
an enhanced ¢rst step.
3.2. TIMP-2-insensitive ¢rst step activation of pro-MMP-2 by
TIMP-2-de¢cient ¢broblasts
To further study these observations in a TIMP-2-free envi-
ronment, we used TIMP-2vEx2;3=vEx2;3 (lacking exons 2 and 3
and thus lacking the MMP inhibitory region at the N-termi-
nus of the protein [18]) and TIMP-2þ=þ primary mouse ¢bro-
blasts and a ras/myc transformed TIMP-23=3 (lacking the
entire TIMP-2 gene [19]) mouse ¢broblast cell line. In the
TIMP-2þ=þ ¢broblasts, pro-MMP-2 activation proceeded
mostly to the fully active species. In TIMP-2vEx2;3=vEx2;3 ¢bro-
blasts, pro-MMP-2 activation occurred in response to Con A
(but not PMA), proceeding mostly to the intermediate form,
with only very minor amounts of fully active MMP-2 (Fig.
2a). We tested the possibility that this small amount of fully
active MMP-2 was due to residual TIMP-2 from the serum.
TIMP-2þ=þ and TIMP-2vEx2;3=vEx2;3 ¢broblasts were cultured
in serum-containing media with or without excess GM6001 (a
synthetic MMP inhibitor) for several days, in order to block
potential TIMP-2 binding sites on the cell surface as previ-
ously described [6]. Cells were then washed extensively in se-
rum-free media (SFM) without GM6001, and assessed for
pro-MMP-2 activation. Under these conditions, we observed
similar amounts of MMP-2 processing to the intermediate
form in the TIMP-2vEx2;3=vEx2;3 cells in response to Con A,
however, noticeably less fully active enzyme was observed
(Fig. 2a). Upon concentration of the conditioned media
from these cells, some TIMP-2 was found in the conditioned
media of TIMP-2vEx2;3=vEx2;3 and TIMP-23=3 cells but none
was detected when these cells were previously cultured with
GM6001 (Fig. 2b). This indicates that some serum-derived
TIMP-2 bound the cells during previous culture of the non-
GM6001-treated cells in serum, and that this was responsible
for the low levels of MMP-2 activation seen in the TIMP-
23=3 and the TIMP-2vEx2;3=vEx2;3 cell cultures. No cell-associ-
ated TIMP-2 was detected by Western blot analysis, however,
we believe that these TIMP-2 levels are below the detection
limit of our assay system. These data con¢rm that the ¢rst
step of pro-MMP-2 activation can proceed in the absence of
TIMP-2.
In the TIMP-2vEx2;3=vEx2;3 cells, pro-MMP-2 activation was
rescued by the addition of wild-type TIMP-2 (Fig. 2c). We
observed the expected biphasic response whereby increasing
TIMP-2 concentrations initially facilitated pro-MMP-2 activa-
tion, but became inhibitory at higher concentrations. Of note,
it was the second step that was preferentially stimulated in
response to TIMP-2. We also analyzed immortalized ras/
myc transformed TIMP-23=3 ¢broblasts which behaved sim-
ilarly to the TIMP-2vEx2;3=vEx2;3 cells. These TIMP-23=3 cells
also activated pro-MMP-2 in response to Con A, but only to
the intermediate form (Fig. 2d), as reported previously [24].
Upon titration of recombinant TIMP-2, pro-MMP-2 activa-
tion was stimulated, and although it was the second step that
was preferentially potentiated, some e¡ect on the ¢rst step was
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evidenced by loss of intensity in the pro-MMP-2 band (Fig.
2d). This e¡ect is speci¢c for TIMP-2 as TIMP-1 did not
potentiate or inhibit pro-MMP-2 activation (Fig. 2e).
3.3. Con¢rmation of MMP-2 HXCD requirement for
pro-MMP-2 activation
Because TIMP-2 was not required for ¢rst step activation
of pro-MMP-2, we asked whether pro-MMP-2 could be acti-
vated to the intermediate form by random interactions with
MT1-MMP independently of TIMP-2. We cultured ML20-
MT1 cells that lack endogenous MMP-2 with either full-
length MMP-2 or MMP-2 vHXCD (lacking the HXCD).
Although full-length pro-MMP-2 was activated by these cells
in response to Con A, MMP-2 vHXCD was not (Fig. 3a),
con¢rming that the HXCD of MMP-2 is essential for activa-
tion, as previously described [25^28].
We used ala+TIMP-2 to further explore the role of MMP-2
HXCD in this alternate activation mechanism. Ala+TIMP-2
Fig. 1. a: ML20-MT1 cells were plated in a 96-well plate and washed 3U in SFM. The cells were then incubated in fresh SFM containing 100
ng/ml rMMP-2, without or with Con A (20 Wg/ml) stimulation, and without or with TIMP-2 as indicated. After 24 h, the conditioned media
were analyzed by zymography. b: ML20-MT1 cells were treated as in a, except that the cells were plated in a 24-well plate and all treated with
Con A and with the indicated concentrations of TIMP-2. MMP-2 was then concentrated from the conditioned media using gelatin^agarose
beads and the bound fractions analyzed by Western analysis for MMP-2. The relative levels of pro- and active MMP-2 were determined by
scanning densitometry using molecular dynamics software and plotted as a percentage of the fully active enzyme. c: ML20-MT1 cells were
treated as in a, except that the cells were treated with Con A and with TIMP-1 and/or TIMP-2 as indicated. The relative migrations of pro-,
intermediate, and fully mature MMP-2 are indicated at 72, 64, and 62 kDa, respectively.
FEBS 27729 9-10-03
M.A. La£eur et al./FEBS Letters 553 (2003) 457^463 459
contains an added N-terminal alanine and thus does not bind
the MMP active site but can still bind the HXCD of MMP-2
[15]. Using an MMP-2 activity-based assay (Chemicon), ala+
TIMP-2 showed no inhibitory activity against the catalytic
domain of MMP-2 while rTIMP-2 blocked gelatin degrada-
tion (data not shown), con¢rming that the ala+TIMP-2 mu-
tant protein cannot bind the active site of MMP-2. In activa-
tion studies, ala+TIMP-2 blocked pro-MMP-2 activation at
both steps in the ML20-MT1 cell system (Fig. 3b), suggesting
that both mechanisms involve a region of HXCD that binds
TIMP-2 (or nearby), and that ala+TIMP-2 blocks an essential
requirement of HXCD binding. Although such data has been
interpreted in the past to implicate TIMP-2 in the ¢rst step,
the lack of TIMP-2 in our system would suggest some other
binding partner for the same/similar region of the MMP-2
HXCD.
4. Discussion
Strongin and co-workers [8] were the ¢rst to report a com-
plex comprising MT1-MMP, TIMP-2 and MMP-2 associated
with the cell surface. It was therefore proposed that the MT1-
MMP/TIMP-2 complex could act as a receptor for pro-MMP-
2, which in turn could be activated by a TIMP-2-free MT1-
Fig. 2. a: Primary TIMP-2þ=þ or vEx2;3=vEx2;3 mouse ¢broblasts were plated in a 96-well plate without or with 1 WM GM6001. The cells were
then washed 4U (including one overnight wash) in SFM, followed by incubation in fresh SFM for 48 h either unstimulated (U), or stimulated
with Con A (20 Wg/ml) (C) or PMA (1037 M) (P). The conditioned media were analyzed by zymography. b: The conditioned media from
TIMP-2þ=þ and TIMP-2vEx2;3=vEx2;3 ¢broblasts (1‡ Fb) (concentrated 6U) or TIMP-23=3 ¢broblasts (concentrated 25U) cultured without or
with 1 WM GM6001 were subjected to TIMP-2 Western analysis. TIMP-2 has a molecular weight of 21 kDa. c: Primary TIMP-2vEx2;3=vEx2;3
mouse ¢broblasts were treated as described in a, except with the indicated concentrations of rTIMP-2 and Con A (20 Wg/ml). d: TIMP-23=3
¢broblasts were treated as in a, except with the indicated concentrations of rTIMP-2 and Con A (20 Wg/ml). e: TIMP-23=3 ¢broblasts were
treated as in d, except that rTIMP-1 was used instead of rTIMP-2.
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MMP molecule in close proximity. It was also shown that
upon titration of exogenous TIMP-2, the rate of pro-MMP-
2 activation was initially increased, and then fully inhibited
with high amounts of TIMP-2 [8]. Further studies by Butler et
al. [6] using TIMP-2-depleted HT1080 membranes demon-
strated again the biphasic response of wild-type TIMP-2 on
pro-MMP-2 activation. N-terminal TIMP-2 could not poten-
tiate this activation but could still block MT1-MMP function,
demonstrating the requirement for the TIMP-2 C-terminal
domain in the activation process. Similar results were also
reported by Kinoshita et al. [7] using MT1-MMP immobilized
on agarose beads. These data, combined with the requirement
of the HXCD of MMP-2 and MT1-MMP for activation [25^
28], have led to the notion that the trimolecular complex
(MT1-MMP/TIMP-2/MMP-2) was involved in the initial
step of pro-MMP-2 activation.
Our observations in the ML20-MT1 and TIMP-2-de¢cient
cell systems suggest that TIMP-2 is more critically important
for the second MMP-2-activational step rather than the ¢rst.
In ¢broblasts from TIMP-2-de¢cient mice, generation of the
intermediate form of MMP-2 occurred in the absence of
TIMP-2. Titration of exogenous TIMP-2 caused a preferential
increase in the generation of the fully active enzyme. Our
results also show that this is not simply due to increased
generation of the intermediate form, which is then rapidly
processed to the fully active enzyme. Co-addition of TIMP-
1, which arrested MMP-2 activation to the intermediate form
by blocking the TIMP-2-stimulated second step, revealed that
some ¢rst step increase was due to added TIMP-2, but this
was much less than that seen in the second step. Thus a
TIMP-2-independent ¢rst activational step appears to supple-
ment the well-characterized TIMP-2-dependent mechanism.
In favor of the TIMP-2-independent ¢rst step processing
discussed herein, others have also reported TIMP-2-indepen-
dent generation of intermediate MMP-2. In isolated mem-
branes depleted of TIMP-2, MT1-MMP was able to activate
pro-MMP-2 to the intermediate form, but fully active MMP-2
was observed only upon addition of TIMP-2 [6,29]. Further-
more, Miyamori et al. discovered that pro-MMP-2 was acti-
vated in HEK 293 cells that did not express detectable levels
of TIMP-2, but only to the intermediate form. Upon addition
of TIMP-2, however, the fully active species was generated
[30]. Incubation of HT1080 membranes with pro-MMP-2
and increasing amounts of an anti-TIMP-2 antibody blocked
the generation of the fully active enzyme while the intermedi-
ate form persisted [8]. Using a reactive site-modi¢ed TIMP-2
that can only bind via C-terminal interactions with pro-MMP-
2, it was demonstrated that this modi¢ed TIMP-2 could block
formation of fully active MMP-2 in Con A-stimulated
HT1080 cells, but the intermediate form of MMP-2 persisted
[31]. Previous publications describing data from TIMP-2-de¢-
cient ¢broblasts have shown defects in pro-MMP-2 activation
in TIMP-2-null cells compared to wild-type control cells
[18,19]. Wang et al. concluded that no intermediate or fully
active MMP-2 forms were detected in their TIMP-23=3 cells.
However, closer analysis showed ¢rst step activation in re-
sponse to Con A [19] and this was con¢rmed by Morrison
et al. [24]. Caterina et al. [18] indicated that cells derived from
Fig. 3. a: ML20-MT1 cells were plated in a six-well plate and washed 3U in SFM. The cells were then incubated in fresh SFM (without or
with Con A, 20 Wg/ml) containing the conditioned media of MCF-7 cells transfected with either full-length MMP-2 or MMP-2 vHXCD. After
24 h, the conditioned media were analyzed by zymography. b: ML20-MT1 cells were plated in a 96-well plate and treated as in a, except
rMMP-2 was used (100 ng/ml) and treated with the indicated concentrations of ala+TIMP-2 (without or with Con A, 20 Wg/ml).
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their TIMP-2vEx2;3=vEx2;3 mice were defective in pro-MMP-2
activation. Their data also showed ¢rst step activation when
stimulated with Con A, and that titration of recombinant
TIMP-2 selectively enhanced the second activational step.
Our data therefore consolidate observations made by others
using TIMP-2-de¢cient cell systems where persistence of the
intermediate form, but not the fully active form of MMP-2
was noted but not investigated further.
Importantly, we con¢rmed a critical role of the MMP-2
HXCD in pro-MMP-2 activation as previously described
[8,25^28]. MMP-2 vHXCD did not show any activation in
our system, arguing against random interactions between
MT1-MMP and pro-MMP-2 allowing ¢rst step activation.
Ala+TIMP-2 also inhibited pro-MMP-2 activation, presum-
ably due to stearic hindrance of important interactions be-
tween cell surface molecules and the MMP-2 HXCD. The
inhibition seen with ala+TIMP-2 suggests that the region of
the MMP-2 HXCD required for TIMP-2-independent ¢rst
step processing is masked by ala+TIMP-2 binding.
We have examined possible alternative tethering of pro-
MMP-2 to the cell surface for ¢rst step activation. MMP-2
has been shown to bind via its HXCD to heparin, resulting in
increased MMP-2 activation [32,33], however, experiments us-
ing heparinase enzyme (data not shown) suggest that heparin-
containing molecules do not act as MMP-2 receptors for ¢rst
step activation. The HXCD of MMP-2 can bind ¢bronectin
[28,33], however, addition of ¢bronectin to our culture sys-
tems did not perturb MMP-2 activation (data not shown),
suggesting that ¢bronectin does not participate in pro-
MMP-2 activation in this model. MMP-2 can also bind type
I collagen, however, Murphy et al. [34] demonstrated that
MMP-2 lacking the type II ¢bronectin-like repeats could
not bind type I collagen, but was fully capable of pro-
MMP-2 activation, suggesting that collagen is also not likely
to act as an alternate MMP-2 receptor involved in this alter-
nate activation model. Another candidate would be the integ-
rin KvL3, which has been shown to bind MMP-2 through the
HXCD [35]. The involvement of this integrin in pro-MMP-2
activation, and speci¢cally in MMP-2 HXCD binding, has
been postulated since co-transfection of MCF-7 cells with
MT1-MMP and L3 integrin facilitated the progression of the
intermediate form to the fully active form [36,37]. As with
others [36,37], we ¢nd very little KvL3 integrin in our MCF-7
cells (data not shown), such that this is also not likely to
facilitate ¢rst step binding in the ML20-MT1 model. Another
possibility is that the binding of MMP-2 to the cell surface is
of low a⁄nity and ‘non-speci¢c’, but still mediated by the
HXCD. This would seem unlikely, since Emonard et al. char-
acterized MMP-2 binding to MCF-7 cells and found it to be
relatively high a⁄nity (Kd = 2U1039 M) [38]. They further
Fig. 4. Current and alternate models of pro-MMP-2 activation.
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suggested that this may be mediated by MT1-MMP-tethered
TIMP-2 complexes [39], however, MT1-MMP is undetectable
in MCF-7 cells in our laboratory.
In conclusion, we have documented in two independent cell
systems a signi¢cant level of TIMP-2-independent ¢rst step
processing of pro-MMP-2, con¢rming some inconsistencies
observed by others in the currently accepted dogma of pro-
MMP-2 activation. We therefore propose an additional model
for pro-MMP-2 activation that would at least supplement the
established model (Fig. 4): Pro-MMP-2 binds an alternate
binding site on the cell surface through its HXCD. The inter-
mediate form of MMP-2 is then generated following the cleav-
age of the propeptide by a TIMP-free MT1-MMP molecule.
Following this cleavage, the intermediate form is released
from its primary binding site and binds to the C-terminal
domain of TIMP-2, which in turn binds MT1-MMP to
form the trimolecular complex. Although we have no data
for this step, it is implied by the clear requirement of
TIMP-2 for the second step. A conformational change in
MMP-2 may account for this event, whereby the HXCD of
the intermediate form of MMP-2 would display a greater
a⁄nity for the C-terminal domain of TIMP-2 than the pro-
form, however, this remains to be proven. Two trimolecular
complexes are then brought in close proximity to promote the
autocatalytic activation of MMP-2, thus generating the fully
active enzyme.
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